2-[2-(3-Methoxyphenyl)-2-adamantyl]ethanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[2-(3-Methoxyphenyl)-2-adamantyl]ethanamine
• 化学式: C₁₉H₂₇NO
• 分子量: 285.4
• InChiKey: LVPMGUNHCIWIRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
  申请人：——

  公开号：US20030207881A1

  公开（公告）日：2003-11-06

  The use of a compound of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen, alkyl, aryl and non-aromatic heterocyclic groups, or each of one or more pair(s) of the substituent groups R 1 to R 6 may together form a 3, 4, 5, 6, 7 or 8-membered ring containing 0, 1 or 2 heteroatom(s); R 7 is selected from alkyl, aryl and non-aromatic heterocyclic groups, and R 8 is selected from hydrogen, halogen, alkyl, aryl and non-aromatic heterocyclic groups; and pharmaceutically acceptable salts and prodrugs thereof, in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission; novel compounds of formula (1) per se and for use in therapy. 1

  本发明涉及使用化合物的公式（I）：其中R1、R2、R3、R4、R5和R6独立选择氢、烷基、芳基和非芳香杂环基团，或者其中一对或多对取代基R1到R6可以共同形成一个包含0、1或2个杂原子的3、4、5、6、7或8元环；R7选择烷基、芳基和非芳香杂环基团，R8选择氢、卤素、烷基、芳基和非芳香杂环基团；以及其药学上可接受的盐和前药，在制造用于治疗通常与谷氨酸能传递异常有关的疾病的药物中使用；本发明涉及公式（1）的新化合物本身及其在治疗中的使用。
• 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1305306A2

  公开（公告）日：2003-05-02
• US6828318B2
  申请人：——

  公开号：US6828318B2

  公开（公告）日：2004-12-07
• [EN] 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION<br/>[FR] NOUVELLES 2-ADAMANTYLETHYLAMINES ET LEUR UTILISATION DANS LE TRAITEMENT D'ETATS GENERALEMENT ASSOCIES A DES ANOMALIES DE LA TRANSMISSION GLUTAMATERGIQUE
  申请人：VERNALIS RES LTD

  公开号：WO2002008219A2

  公开（公告）日：2002-01-31

  The use of a compound of formula (1): wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl, aryl and non-aromatic heterocyclic groups, or each of one or more pair(s) of the substituent groups R1 to R6 may together form a 3, 4, 5, 6, 7 or 8-membered ring containing 0, 1 or 2 heteroatom(s); R7 is selected from alkyl, aryl and non-aromatic heterocyclic groups, and R8 is selected from hydrogen, halogen, alkyl, aryl and non-aromatic heterocyclic groups; and pharmaceutically acceptable salts and prodrugs thereof, in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission; novel compounds of formula (1) per se and for use in therapy.